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HIGHLIGHTS
 MDEB potentiates store-operated Ca2+ entry in various cancer cell lines
 The action of MDEB is more specific than that of the generally used inhibitor 2-APB
 MDEB has a strong stimulatory effect of PHA-mediated Ca2+ increase in Jurkat cells
 MDEB increases apoptosis in fully activated Jurkat cells
 MDEB may represent the first member of a new family of immunomodulators
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HIGHLIGHTS
 MDEB potentiates store-operated Ca2+ entry in various cancer cell lines
 The action of MDEB is more specific than that of the generally used inhibitor 2-APB
 MDEB has a strong stimulatory effect of PHA-mediated Ca2+ increase in Jurkat cells
 MDEB increases apoptosis in fully activated Jurkat cells
 MDEB may represent the first member of a new family of immunomodulators
ABSTRACT
Store-operated Ca2+ entry (SOCE) is the main Ca2+ entry pathway of non-excitable 
cells. In the past decade, the activation of this entry has been unveiled, with STIM1, a protein 
of the endoplasmic reticulum able to sense the intraluminal Ca2+ content, and Orai1, the pore-
forming unit of the Ca2+ release activated Ca2+ (CRAC) channels. When Ca2+ ions are 
released from the endoplasmic reticulum, STIM1 proteins oligomerize and directly interact 
with Orai1 proteins, allowing the opening of the CRAC channels and a massive Ca2+ ion 
influx known as SOCE. As Ca2+ is involved in various cellular processes, the discovery of 
new drugs acting on the SOCE should be of interest to control the cell activity. By testing 
analogues of 2-aminoethyl diphenylborinate (2-APB), a well known, though not so selective
effector of the SOCE, we identified methoxy diethylborinate (MDEB), a molecule able to 
potentiate the SOCE in three leukocyte and two breast cancer cell lines by increasing the Ca2+
influx amplitude. Unlike 2-APB, MDEB does not affect the Ca2+ pumps or the Ca2+ release 
from the endoplasmic reticulum. MDEB could therefore represent the first member of a new 
group of molecules, specifically able to potentiate SOCE. Although not toxic for non-
activated Jurkat T cells, it could induce the apoptosis of phytohemagglutinin-stimulated cells.
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1. INTRODUCTION
Ca2+ signalling is involved in various cellular processes like activation, proliferation
and migration [1]. Due to this key role in cell physiology, the discovery of drugs acting on 
Ca2+ signalling is of major interest. Thus, cyclosporine and FK-506 are usually used in 
treatment after engraftment to inhibit calcineurin, a Ca2+-dependent phosphatase which is 
absolutely required during T cell activation [2]. Upstream the Ca2+ signalling are the various 
Ca2+ channels, and the control of channel activity by drugs is a common theme in
pharmacology.
When T cells are stimulated via the T cell receptor, inositol 1,4,5-trisphosphate (IP3)
is synthesised which induces, after the activation of the IP3 receptor (IP3R), the release of 
Ca2+ ions from the endoplasmic reticulum (ER). This release causes in turn the opening of the
Ca2+ release activated Ca2+ channels (CRAC channels) [3] of the plasma membrane, allowing 
a massive Ca2+ influx known as store-operated Ca2+ entry (SOCE), which is necessary for the 
T cell activation [4]. Thus, a sustained increase of the resting cytosolic calcium concentration 
([Ca2+]cyt) must persist for at least 2 hours to induce the full T cell commitment [5-7]. SOCE
channels have been first characterized on mast cells and T lymphocytes in the early 90s [8, 
9]. Recently, the key proteins responsible for the SOCE have been identified with STIM1 
(stromal interaction molecule 1) acting as a Ca2+ sensor in the ER, and Orai1 representing the 
plasma membrane resident CRAC channel pore [10, 11]. It has been shown that after cell 
stimulation and Ca2+ release by the ER, STIM1 proteins oligomerize and translocate in the 
ER toward the plasma membrane where they physically interact with Orai1 channels to allow 
their opening whereby the resulting Ca2+ influx is instrumental to sustain the increase of the 
cytosolic Ca2+ concentration ([Ca2+]cyt) [12].
Mutations of STIM1 or Orai1 genes, responsible for the absence or deficiency of the 
corresponding protein, induce a severe combined immunodeficiency (SCID) phenotype: T 
cells are well developed, but cannot be activated [11]. There exist two Orai1 paralogues, 
Orai2 and Orai3. The three Orai proteins can elicit SOCE when expressed in a heterologous 
system [13-15]. However, only Orai1 expression can fully correct the SCID phenotype in 
Orai1-deficient cells [13], highlighting the key role of Orai1 in lymphocyte activation, 
whereas Orai2 and Orai3 functions are still to be elucidated. However, it has recently been 
proposed that Orai2 and Orai3 channels are the channels responsible for the native SOCE in 
dendritic cells and estrogen receptor positive breast cancer cells respectively [16, 17].
Furthermore, the arachidonate-regulated Ca2+ channel is made of a Orai1/Orai3 mixed 
proteins [18].
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Due to its key role, it is of interest to develop effectors of the SOCE that could 
represent new immunomodulators or a new way to cure cancers as e.g. leukemias. Econazole 
and ketotifen, two compounds known to block the SOCE have already been described to 
purge bone marrow of leukemia cells suggesting a higher sensitivity of these cells to SOCE 
inhibitors [19]. 
The aim of this study therefore was to develop new effectors of SOCE. Interestingly, 
2-aminoethyl diphenylborinate (2-APB, Fig. 1), commonly used to inhibit SOCE, seems to be 
the most promising molecule, as it has a dual effect on SOCE: potentiating at 1-5 µM and
inhibiting at > 30 µM [20]. Unfortunately 2-APB lacks specificity as it can also affect the 
function of various other Ca2+-transporting mechanisms. Depending on the oncentration, 2-
APB can inhibit IP3Rs, sarco- and endoplasmic Ca
2+ ATPase (SERCA) pumps, as well as
some transient receptor potential (TRP) channels of the TRPC family [21-25] while opening
some members of the TRPV family [26, 27]. A few teams have already documented the 
synthesis of 2-APB analogues, but only with the purpose of developing more specific
inhibitors [28-32].
In an attempt to determine which part of the 2-APB molecule is needed for the SOCE 
potentiating and/or inhibiting ability, we previously recorded SOCE in three leukemia cell 
lines in the presence of 2-APB or of several analogues and reported that the boron-oxygen 
core (BOC) of the molecule is necessary for the potentiating capacity [33]. However, when 
the free rotation of the two phenyl groups is blocked or when they are replaced by larger 
groups like benzothienyl groups, Ca2+ influx potentiation is impaired [34]. A drawback was 
that all the new potentiating molecules we identified were still inhibitory at high 
concentrations [33].
In this new study, we therefore focussed our interest on a new 2-APB analogue, 
methyl diethylborinate (MDEB, Fig. 1), which almost only contains the BOC. MDEB is the 
first molecule only able to potentiate the SOCE, without any inhibitory action, and therefore 
could represent the first member of a promising family. Indeed, when used alone, MDEB 
does not show any effect on Jurkat cell viability. However MDEB inhibits the synthesis of 
interleukin-2 by partially activated cells and also induces the apoptosis of fully activated
Jurkat T cells. Thus, it appears that MDEB could specifically eliminate fully activated cells. 
2. MATERIAL AND METHODS
2.1. Cells
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Jurkat (acute T cell leukemia), BL-41 (Burkitt B lymphoma), U937 (monocytic cell 
line), MDA-MB231 and BT-20, two breast carcinoma (BC) cell lines, were from ATCC. 
Leukocyte cell lines were basically maintained in RPMI-1640 medium (Lonza, Verviers, 
Belgium) supplemented with 10 % heat-inactivated fetal calf serum and 2 mM L-glutamine.
BC cell lines were maintained in DMEM medium (Lonza, Verviers, Belgium) supplemented 
with 10 % heat-inactivated fetal calf serum and 2 mM L-glutamine. L15 fibroblasts stably 
overexpressing IP3R1 [35] were a generous gift of Pr Mikoshiba (RIKEN Brain Science 
Institute, Japan). They were maintained in DMEM medium (Gibco®, Life Technologies, 
Gent, Belgium) supplemented with 10 % heat-inactivated fetal calf serum, 3.8 mM L-
glutamine, 1% non-essential amino acids, 85 IU ml-1 penicillin, 85 g ml-1 streptomycin, 400 
g ml-1 geneticin and 25 mM Na-Hepes (pH 7.4). Epstein-Barr Virus immortalized B cells 
from Orai1-deficient and healthy patients were a kind gift of Dr Picard and Pr Fischer (Study 
center of primary immunodeficiencies, AP-HP, Hôpital Necker, Paris, France). Written 
informed consent was obtained from the parents of the patients. The experiments were 
conducted after approval was given by the institutional review boards at Necker–Enfants 
Malades Hospital (Paris, France). All cell lines were maintained at 37 °C in a 5% CO2
humidified atmosphere, except for L15 fibroblasts which were maintained at 10% CO2.
2.2. Measurement of cytosolic Ca2+ concentration ([Ca2+]cyt)
[Ca2+]cyt was recorded by a fluorimetric ratio technique [36, 37]. Leukocytes were 
spun and resuspended at a density of 106 cells/ml in Phosphate-Buffered Saline (PBS) 
supplemented with 1 mg/ml bovine serum albumin and incubated in the dark with 4 μM 
Fura-2-AM for one hour at room temperature under slow agitation. Cells were then 
centrifuged and resuspended in Ca2+-free Hepes Buffered Saline solution (HBS; 135 mM 
NaCl, 5.9 mM KCl, 1.2 mM MgCl2, 11.6 mM Hepes, 11.5 mM glucose adjusted to pH 7.3 
with NaOH) prior to measurement. After centrifugation, 0.5 to 1 x 106 cells were suspended 
in 2 ml HBS in a quartz cuvette and inserted into a spectrofluorophotometer (RF-1501 
Shimadzu Corporation, Kyoto, Japan) connected to a PC computer (Dell Computer Corp., 
Montpellier, France). BC cells were grown on glass coverslips, and prior experiments, rinsed
with PBS. The coverslips were incubated for 30 minutes with 1 mM Ca2+-containing HBS
supplemented with 4 µM Fura-2-AM. Prior to experiments, glass coverslips were inserted in 
a 2 ml Ca2+-free HBS-containing cuvette. A temperature of 37°C was maintained by 
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circulating water from a bath. Ultraviolet light of 340 and 380 nm were used for excitation of 
Fura-2, and emission at 510 nm was recorded. Background and autofluorescence of the cell 
suspension were subtracted from the recordings. The maximum Fura-2 fluorescence (Rmax) 
was obtained by adding 1 μM ionomycin to the cell suspension in the presence of 10 mM 
CaCl2. Minimum fluorescence was determined following depletion of external Ca
2+ with 5 
mM EGTA. [Ca2+]cyt was calculated according to the equation [Ca
2+]cyt = Kd (R-Rmin)/(Rmax-
R), where Kd is the apparent dissociation constant of Fura-2-calcium complex (250 nM), and 
R is the ratio of fluorescence values recorded at 510 nm after excitation at 340 and 380 nm
[36]. In a large number of experiments, cells placed into a quartz cuvette, were treated with 1 
μM thapsigargin (TG) during 10 min in Ca2+-free HBS to induce Ca2+ release from the ER 
and the opening of SOCE channels [37]. Then, 1 mM CaCl2 was added to measure the 
change in [Ca2+]cyt subsequently to Ca
2+ calcium influx [37]. At the end of each experiment, 1 
µM GdCl3 was added to verify that MDEB only acts on the SOCE [17].
2.3. Measurement of SOCE channel activity via Mn2+ quenching
To study directly the divalent ion influx through the SOCE channels, we performed 
Mn2+ quenching experiments. Mn2+ ions bind to Fura-2 and quench the 510 nm emission 
wavelength fluorescence after excitation at 360 nm. The decrease of fluorescence is directly 
dependent on the Mn2+ entry through SOCE channels. For measurements, cells were treated 
for 10 min with 1 µM TG, whereupon 100 µM MnCl2 was added instead of CaCl2. To test the 
effects of MDEB on the Ca2+ release from the ER, the Jurkat cells were stimulated with 10 
µg/ml PHA instead of TG, still in the absence of extracellular Ca2+. PHA cross-links the T 
cell receptor (TCR), inducing the synthesis of IP3 and Ca
2+ release through the IP3Rs [37]. 
Cells were pre-treated for 5 min with MDEB and then stimulated with 10 µg/ml PHA. Values 
are representative of at least 3 independent experiments.
2.4. Down-regulation of Orai1
MDA-MB231 cells were seeded in a 6 well-plate on day 1 (2.105 cells/well). At day 2, 
cells were transfected with the Lipofectamine® RNAiMax (Life Technologies, SAS, Saint 
Aubin, France) according to the supplier recommandations together with 100 nM of Orai1 
siRNA or of a scrambled siRNA (FlexiTube, Qiagen, SAS. Courtaboeuf, France). After 3 
days, cells were used for [Ca2+]cyt measurement (see 2.2) or for extraction of proteins. For 
cellular protein extraction, cells were lysed using RIPA buffer (50 mM Tris-HCl pH8, 150 
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mM NaCl, 1% Triton X100, 0.5% deoxycholate, 0.2% SDS and 0.2 mM EDTA) 
supplemented with an antiprotease pellet (cOmplete Mini, Roche Diagnostics, Meylan, 
France).  SDS-PAGE electrophoresis (10%) was subsequently performed (50 µg 
proteins/lane). Proteins from the gels were electrotransferred onto Hybond ECL membrane 
(Amersham-GE Healthcare, Velizy-Villacoublay, France). After blocking with 5% non-fat 
dry milk dissolved in Tris-buffered saline containing 0.1% Tween 20 (“Tris buffer”) for 1h at 
room temperature, blots were washed three times with Tris buffer and probed 3h with 
specific primary antibody in 5 % non-fat dry milk in Tris buffer. The primary antibodies used 
against Orai1 (1:1000) and actin (1:500) were from Sigma-Aldrich, Saint Quentin Fallavier, 
France). The anti-actin antibody was used to verify that equal amounts were loaded in each 
lane. Detection was performed using the enhanced chemiluminescence reagent (ECL Western 
blotting detection reagents, Amersham-GE Healthcare). Quantification of the bands was 
performed with the ImageJ software.
2.5. Patch-clamp measurements
Cells for patch-clamp experiments were allowed to adhere to a poly-D-ornithine-
coated Petri dish for 10 min. Each dish was then rinsed twice with the bath solution 
containing 160 mM NaCl, 4.5 mM KCl, 10 mM CaCl2 (or 1 mM when indicated), 1.2 mM 
MgCl2, 5 mM Hepes, adjusted to pH 7.4 with NaOH, and kept in this solution during the 
complete experiment. Pipettes were pulled from borosilicate glass capillaries (GC150F, Clark 
Electromedical Instruments, England). Membrane currents were recorded using a Heka EPC9 
amplifier (Heka Elektronik, Lambrecht, Germany) interfaced to a PC computer (Dell
Computer Corp.). Current were sampled at 5 kHz and filtered at 2.9 kHz. Voltage-clamp 
protocols were implemented and data analyzed using Pulse/Pulsefit softwares (Heka 
Elektronik, Lambrecht, Germany). Data were corrected for the liquid junction potential. ICRAC
was mainly recorded in the whole-cell configuration using the following pipette solution: 140 
mM Cs-aspartate, 2 mM MgCl2, 10 mM BAPTA (or EGTA when indicated), 10 mM Hepes, 
pH adjusted to 7.2 with CsOH [37]. Typical resistance of the pipette was 10-15 M. The 
chelation of Ca2+ ions by BAPTA / EGTA induced the passive depletion of the stores, and the 
opening of the CRAC channels [37]. Just after reaching the whole-cell configuration, the 
holding potential (VH) was set to 0 mV to minimize the basal Ca
2+ influx. The Jurkat cells
have a capacitance of 6.6 ± 0.3 pF (n > 50). ICRAC was evoked by applying a 100 ms step to -
100 mV every 2 s; the current amplitude was calculated and expressed as current over cell 
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capacitance. ICRAC time course was monitored over ~ 15-20 min time range by measuring 
ICRAC amplitude 5 ms after pulse clamping every 2 s. At the end of all the experiments, 1 µM 
GdCl3 was added to inhibit ICRAC. The remaining current was considered the leak current.
2.6. Unidirectional 45Ca2+ flux experiments
L15 fibroblasts were seeded in gelatin-coated 12-well plates (Greiner, Frickenhausen, 
Germany) at a density of 60 000 cells per well. Experiments were carried out on confluent 
cell monolayers, 7 days after seeding. 45Ca2+ unidirectional flux experiments were performed 
at 30 C on saponin-permeabilized cells, essentially as described [38]. Permeabilization was 
for 10 min in a solution containing 120 mM KCl, 30 mM imidazole-HCl (pH 6.8), 2 mM 
MgCl2, 1 mM ATP, 1 mM EGTA and 40 µg ml
-1 saponin. The non-mitochondrial Ca2+ stores 
were subsequently loaded for 45 min in 120 mM KCl, 30 mM imidazole-HCl (pH 6.8), 5 mM 
MgCl2, 5 mM ATP, 0.44 mM EGTA, 10 mM NaN3 and 150 nM free 
45Ca2+ (28 μCi ml-1). 
Efflux was initiated by incubation in efflux medium (120 mM KCl, 1 mM EGTA, 30 mM 
imidazole-HCl pH 6.8) containing TG (10 µM) and the indicated concentrations of MDEB. 
Every two minutes the medium was replaced and the Ca2+ release from the stores assessed.
At the indicated time point IP3 (0.7 µM) was added to the efflux medium for 2 min to elicit 
IP3-induced Ca
2+ release. To assess its potential effect on the ATP-driven Ca2+ uptake in the 
stores, MDEB was added in separate experiments during the 45Ca2+-loading phase. 
Alternatively, TG (2 M) was added during this phase to completely block SERCA activity. 
By subtraction of the TG-insensitive Ca2+ uptake from the total uptake for the various 
conditions [39], the active Ca2+ uptake in the ER was calculated and compared.
2.7. Interleukin-2 (IL-2) assay
48-well plates were seeded with 106 Jurkat T cells per well. Cells were then incubated 
for 24 h with 0, 1 or 10 µg/ml PHA and 0 to 1 mM MDEB in complete culture medium. After 
24 h, supernatants were collected and IL-2 amounts were quantified using a Quantikine 
Human IL-2 Immunoassay (R&D Systems Europe, Lille, France). Optical density (OD) was 
measured at 450 nm using a Victor3 plate reader (Perkin Elmer, Courtaboeuf, France). The 
concentration of supernatant IL-2 was determined from the OD curve obtained with the 
standard. Results were the mean of four repeats. In parallel plates, cell viability was accessed 
after treatment with trypan blue by counting with a Malassez hematimeter.
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2.8. Apoptosis detection by TUNEL method
We measured the apoptosis levels in Jurkat cells by the "in situ cell death detection"
kit (Roche Applied Science, Meylan, France). Briefly, 50 000 cells/well were seeded in a 96-
well plate and treated with or without 10 µg/ml PHA and 1 mM MDEB for 6, 12 or 24 h. 
Then according to the manufacturer’s instructions, cells were spun, fixed, permeabilized and 
the Terminal transferase dUTP Nick End Labelling (TUNEL) reaction was performed during 
60 min at 37°C in darkness. For visualization of results, an inverted epifluorescence 
microscope (Axioskop, Karl Zeiss, Le Pecq, France) was used at an excitation wavelength of 
488 nm, and an emission wavelength of 545 nm. Cells were also loaded with 4', 6' –
diamidino-2-phenylindole (DAPI) to visualize the nuclei. Total cell number and TUNEL-
positive cells were counted in several fields and the ratio of apoptotic cells was calculated. 
This experiment was repeated three times.
2.9. Chemicals
2-aminoethoxydiphenyl borate (2-APB), 2-aminoethoxydibutyl borate (2-ABB),
methyl-diethylborinate (MDEB) and trimethylborate (TMB) were from Sigma-Aldrich (Saint 
Quentin Fallavier, France), TG was purchased from Calbiochem-Merck (Nottingham, UK). 
The structures of 2-APB and its analogues are given in Figure 1.
2.10. Statistical analysis
Given values are representative of at least 3 independent experiments and are given as 
mean ± SEM. When used, a t-test < 0.05 is considered as significant.
3. RESULTS
3.1. MDEB has only SOCE potentiating capacity
To visualize the SOCE, we treated the Jurkat cells with 1 µM thapsigargin (TG) in 
Ca2+-free HBS during 10 min to allow the release of Ca2+ ions from the ER and subsequently 
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the opening of the SOCE channel (Fig. 2A, arrow i). Addition of 1 mM CaCl2 induced an 
increase of [Ca2+]cyt due to the entry of Ca
2+ ions through the SOCE channels (Fig. 2A). 
In these conditions, a progressive increase of the MDEB concentration added 30s 
prior CaCl2 (arrow ii) was accompanied by an increase of the peak [Ca
2+]cyt, stabilizing at 
MDEB concentrations  1 mM (Fig. 2A and B). Noteworthy, high MDEB concentrations
were devoid of any inhibition ability, allowing the calculation of an apparent potentiation
constant of 44 ± 11 µM (n = 5, Figs. 2A and B). MDEB potentiation ability peaked at 243 ± 
20 % (n = 5) at a concentration of 1 mM (peak ∆[Ca2+]cyt = 2171 ± 78 nM vs 895 ± 34 nM in 
the absence of MDEB, p < 0.01), followed at higher concentrations by a non-significantly 
different plateau at 216 ± 19 % (n = 5, Fig. 2 B). This MDEB-induced increase of [Ca2+]cyt
was totally abolished by 1 µM GdCl3, showing that MDEB acted on SOCE (Fig. 2A, dashed 
line). In view of this unexpected result, we used 2-APB and 2-ABB (Fig. 1) as controls. As
shown in Figure 2B, 2-APB and 2-ABB had their usual dual effects on Jurkat cell SOCE: 
potentiation at 3 µM ( 220 %) and inhibition at a concentration > 50 µM for 2-APB 
(respectively at 20 and at > 100 µM for 2-ABB). The potentiation amplitude of MDEB, 2-
APB and 2-ABB was however similar (respectively 243 ± 20, 218 ± 21 and 203 ± 17 %). 
Trimethylborate (TMB, Fig. 1), a molecule similar to MDEB (the two ethyl groups 
are replaced by two methoxyl groups) was devoid of any potentiation or inhibition capacity 
(Fig. 2B).
As the [Ca2+]cyt represents the equilibrium between Ca
2+ influx and Ca2+ efflux, it is 
impossible to know directly whether the increase of [Ca2+]cyt is the result of an increase in
Ca2+ entry amplitude or a decrease in Ca2+ exit amplitude. To answer this question, we next 
performed Fura-2 fluorescence quenching experiments with Mn2+ ions. Mn2+ ions enter the 
cell through SOCE channels, but are not pumped back to the extracellular medium as they 
inhibit the Na+/Ca2+ exchanger (NCX) and are not transported by the plasma membrane Ca2+-
ATPases (PMCA) [40-42]. As Mn2+ ions quench the fluorescence of the Fura-2, an 
acceleration of the divalent ion entry is associated with an increase of the quenching rate. As 
shown in Fig. 2C, after a 10 min TG stimulation of Jurkat cells, addition of 100 µM MnCl2
induced a clear decrease of the Fura-2 fluorescence (-0.24 ± 0.01 % F0/s, n = 4). The 
subsequent addition of 1 mM MDEB induced an about 3-fold acceleration of the Fura-2
quenching rate (-0.69 ± 0.03 % F0/s, p<0.05, n = 4). Thus, MDEB is able to enhance the
divalent ion influx.
3.2. MDEB has a potentiating ability on SOCE of various leukocytes
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We next tested MDEB on two other leukocyte cell lines (BL-41, Burkitt B lymphoma 
and U937, monocytic cells).
In the same conditions as for Jurkat cells, MDEB was also able to potentiate the 
SOCE of the two other leukocyte cell lines with a non significantly different potentiation
constant of 58 ± 7 µM (n = 4) and 66 ± 12 µM (n = 5) respectively for BL-41 and U937 cell 
lines vs 44 ± 11 µM for Jurkat cell SOCE (Fig. 3A). MDEB was slightly more powerful on 
BL-41 and U937 cells than on Jurkat cells, increasing the amplitude of the [Ca2+]cyt
respectively to 328 ± 23 % (n = 4) and 282 ± 42 % (n = 5) vs. 243 ± 20 %. 
3.3. MDEB only potentiates the SOCE when Orai1 is expressed
Although 2-APB has a dual effect on Orai1 channels, it only potentiates Orai3 
channels [17, 43]. However, even if T cells express the three Orai isoforms, only the presence 
of Orai1 is requested for the potentiating/inhibiting effects of 2-APB on SOCE [33]. To 
verify that Orai1, and not the other Orai isoforms, is also the target of MDEB in physiological 
conditions, we compared wild type B cell that express all 3 Orai isoforms and a B cell line 
which only express Orai2 and Orai3 but not Orai1 [44]. TG treatment in absence of 
extracellular Ca2+ ions clearly induced the same kind of Ca2+ release from the ER of B cells 
expressing Orai1 ("B-Orai1 wt") or from Orai1-deficient B cells ("B-Orai1 deficient", new 
Fig. 3B). However, after readdition of extracellular Ca2+ ions, the [Ca2+]cyt increased by ~ 900 
nM (896 ± 58 nM, n = 5) in cells expressing Orai1. In contrast, with the same protocol, 
extracellular Ca2+ readdition only induced a rise of 75 ± 18 nM (n = 5, Fig 3B) in Orai1-
deficient cells, which is significantly less than in cells expressing Orai1 (-92 %, p < 0.01). 
When 1 mM MDEB was added 200s after Ca2+ ion readdition on Orai1-expressing cells, it 
induced a rebound due to its potentiation ability on the SOCE (maximal increase to 1568 ± 
142 nM, n = 5). In contrast, in cells lacking Orai1, MDEB did not induce any rebound (Fig. 
3B). 
To confirm this result, Mn2+-quenching experiments were performed on these cells. 
Similarly to 2-APB [33], MDEB was able to increase the Mn2+-induced quenching of Fura-2 
only in B cells expressing Orai1: -0.52 ± 0.01 % F0/s vs -0.35 ± 0.01 % F0/s (n = 5, p < 0.01) 
in absence of MDEB (Fig. 3C). Mn2+ ions were not able to induce the Fura-2 quenching in 
Orai1-deficient cells, and MDEB was in these cells without effect (Fig. 3C). The recordings 
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appeared noisier in B cells lacking Orai1 (Fig 3C), probably due to a weaker loading of Fura-
2.
3.4 MDEB has the same potentiating ability on breast cancer cell SOCE
On both BC cell lines, by using the same protocol as for the leukocyte cell lines, 
MDEB also potentiated SOCE but with higher affinity: 25 ± 7 µM (n = 4)  and 14 ± 2 µM (n 
= 4) respectively for the MDA-MB231 and BT-20 cell lines vs. 44 ± 11 nM for Jurkat cells (p 
< 0.05, Fig. 4A). On the contrary, the amplitude of the SOCE increase was significantly 
smaller than in the leukocyte cell lines: 162 ± 4 % (MDA-MB231 cells: 575 ±  24 nM vs. 390 
± 15 nM without MDEB, n = 4) and 166 ± 3 % (BT-20 cells: 581 ± 30 nM vs. 346 ± 16 nM, 
n = 4) vs. 243 ± 20 % (Jurkat cells, Fig. 4B, p < 0.01). 
To verify that Orai1 is also the main protein allowing the SOCE in the BC cell lines, 
we used siRNA targeted against Orai1 in MDA-MB231 cells. As shown in figure 4B, 100 
nM siRNA abolished the expression of Orai1 proteins by 78 ± 6 % (n = 3).
TG treatment in absence of extracellular Ca2+ ions clearly induced the same kind of 
Ca2+ release from the ER of Orai1-expressing MDA-MB231 cells ("control siRNA") or from 
cells in which the expression of Orai1 was largely impaired ("Orai1 siRNA", Fig. 4C), 
showing that important downregulation of Orai1 expression had no effect on the ER Ca2+ ion 
content. After readdition of Ca2+ ions, the [Ca2+]cyt increased by ~ 500 nM (516 ± 20 nM, n = 
5) in cells expressing Orai1. In contrast, using the same protocol, extracellular Ca2+
readdition induced only a rise of 118 ± 21 nM (n = 5, Fig 4C) in the cells in which Orai1 was 
downregulated, which was significantly less than in cells expressing normal Orai1 levels (-77
%, p < 0.01). This result clearly shows that Orai1 is the main responsible for the SOCE in 
MDA-MB231 cells. When 1 mM MDEB was added 200s after Ca2+ readdition on Orai1-
expressing cells, it clearly induced a rebound due to its potentiation ability on the MDA-
MB231 cell SOCE (686 ± 30 nM, n = 5) but was devoid of any significant effect on cells 
with a decreased expression of Orai1 (Fig 4C).
Taken together, the results indicate that in both leukocyte and BC cell lines, MDEB 
had only a potentiating capacity on the SOCE when Orai1 is expressed.
3.4. Competition between 2-APB/MDEB and between 2-ABB/MDEB on Jurkat cell SOCE
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As 2-APB and MDEB have similar structures, we hypothesize that they bind to the 
same site(s), and therefore performed competition experiments between the two molecules. 
For this purpose we used a concentration of 100 µM for all compounds. At this concentration, 
2-APB inhibits ~ 95% of the peak [Ca2+]cyt increase ("∆[Ca2+]cyt",,45 ± 9 nM  vs. 1049 ± 21 
nM, n = 5, p < 0.01, Fig. 5A, green line), while MDEB potentiates this increase (2075 ± 49 
nM  vs. 1049 ± 21 nM, n = 5, p < 0.01, Fig. 5B, cyan line).
As clearly shown in Figure 5A, MDEB was not able to potentiate the SOCE in 
presence of 2-APB (both compounds were added at the same time, arrow ii, green line vs. red 
line, (∆[Ca2+]cyt = 60 ± 9 nM , n = 5, not significantly different to the measured ∆[Ca2+]cyt
with 2-APB alone). Furthermore, when 2-APB had totally impaired the Ca2+ entry, MDEB 
could not reverse the inhibition (orange line, MDEB was added at t = 630 s, arrow iii, 
∆[Ca2+]cyt = 63 ± 10 nM , n = 5, not significantly different to the measured ∆[Ca2+]cyt with 2-
APB alone).
In the parallel experiments (Fig. 5B), we treated the cells with MDEB prior using 2-
APB. Clearly, either when both compounds were added together (Fig. 4B, red line) or even 
when 2-APB was added (arrow iii) after potentiation with MDEB (∆[Ca2+]cyt = 76 ± 8 nM , n 
= 5, not significantly different to the measured ∆[Ca2+]cyt with 2-APB alone), 2-APB totally 
inhibited the Ca2+ entry (Fig. 5B, velvet line vs. cyan line). These results implied that at 
equimolar concentrations, inhibition by 2-APB was stronger than potentiation by MDEB.
In a previous work, we showed that the removal of the two phenyl rings of the 2-APB 
molecule, which leads to 2-ABB, did not impair its potentiation/inhibition capacity, but 
decreased the sensitivity of the SOCE to 2-ABB [33].
As shown in Figure 5C, 100 µM 2-ABB almost totally inhibited the SOCE by ~ 90% 
(∆[Ca2+]cyt = 107 ± 7 nM  vs. 1049 ± 21 nM, n = 5, green line). However, when MDEB was 
added simultaneously with 2-ABB, only an inhibition of 20 % was observed (∆[Ca2+]cyt = 
225 ± 17 nM  vs. 1049 ± 21 nM, n = 5, p < 0.01, red line). Thus MDEB restored   10 % of 
the Δ[Ca2+]cyt. Similarly, when MDEB was added after 2-ABB had fully exerted its inhibitory 
ability, it was able to partially counteract the inhibition (∆[Ca2+]cyt = 184 ± 15 nM  vs. 1049 ± 
21 nM, n = 5, p < 0.01, orange line).
Also, when 2-ABB was added after MDEB exerted its potentiating effect, the SOCE 
was only partially inhibited (∆[Ca2+]cyt = 236 ± 24 nM, n =5, velvet line vs. cyan line, Fig.
5D). These results showed that MDEB could, although only partially, counteract the 
inhibition of the SOCE by the less potent 2-ABB, but not by the more potent 2-APB.
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We next performed experiments where increasing concentrations of MDEB (1 µM to 
30 mM) were applied 30s prior Ca2+ with various inhibiting concentrations of 2-APB (20, 30, 
50 and 100 µM, Fig 5E). The potentiating effect of MDEB was totally abolished by 50 or 100 
M 2-APB even at the highest concentration (30 mM). However at lower concentrations of 2-
APB (20 and 30 µM), MDEB could partly counteract the inhibition due to 2-APB. In the 
presence of 30 mM MDEB + 20 µM 2-APB, 46 ± 4 % (n = 4) of the control ∆[Ca2+]cyt was 
observed vs. 6 ± 1 % with 20 µM 2-APB alone (n = 4, p < 0.01). This value was still however
far from the potentiation capacity of 30 mM MDEB alone (212 ± 8%, n = 4, p < 0.01). These 
results confirm that the inhibition by 2-APB was stronger than the potentiation by MDEB.  
3.5. MDEB increases Jurkat cell ICRAC amplitude
ICRAC is the plasma membrane Ca
2+ current activated by passive depletion of the 
internal stores [37]. Upon break-in with the pipette solution containing 10 mM BAPTA, 
hyperpolarization of the Jurkat cell membrane evoked a weak inward current in the absence 
of external Ca2+ ions (Fig. 6A). Addition of 1 or 10 mM extracellular CaCl2 induced the 
development of an inward current (Fig. 6A), which was inhibited by 1 µM GdCl3 (Fig. 6B
and C), 1 mM CdCl2 or 5 mM NiCl2 (data not shown) and showed a fast inhibition during the 
100 ms pulse. The current/voltage relationships revealed an inwardly rectifying current with a 
reversal potential at a positive voltage (Fig. 6D). The time course of the peak current showed 
that after an increase of the current amplitude, there was a slow inactivation (first 6 min of 
Fig. 6B): furthermore, the high affinity chelating agent BAPTA allowed the development of a 
larger Ca2+ current than the low affinity chelating agent EGTA (Fig. 6B). These kinetic and 
pharmacological characteristics are typical of ICRAC's [45, 46].
In the presence of 10 mM CaCl2 in the bath, 1 mM MDEB quickly increased the 
amplitude of ICRAC (Fig. 6B), and this effect was inhibited by addition of 1 µM GdCl3 (Fig. 
6B and C). As the trace recorded in presence of GdCl3 could be considered as the leak 
through the clamped membrane, we observed a peak amplitude increase at the steady state 
(95-100 ms) from -3.6 ± 0.1 pA/pF to -20.5 ± 0.1 pA/pF (~ 6 fold), followed by a slow decay
(Fig. 6B). Furthermore, when EGTA, a less efficient chelator of Ca2+ ions than BAPTA was 
used in the pipette solution, the peak amplitude increase induced by 1 mM MDEB was 
weaker: from -2.7 ± 0.2 pA/pF to -11.1 ± 0.3 pA/pF (~ 4 fold, p < 0.01, Fig. 6B). As shown 
in Figure 6D, the effect of MDEB on ICRAC was not voltage-dependent as its amplitude was 
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increased at all the voltage values. Thus, these results confirmed that MDEB increased the 
SOCE of Jurkat cells by directly increasing ICRAC amplitude.
3.6. MDEB does not inhibit ER Ca2+ release and sequestration
One of the main limitations of the use of 2-APB as an immunomodulator is its lack of 
specificity and especially the fact that it also inhibits both Ca2+ release from the ER and 
SERCA activity [21]. Some 2-APB analogues have been developed with higher ability to 
block the SOCE, but they still inhibit Ca2+ release [30, 33, 47].
To test the possibility that MDEB inhibits the Ca2+ release from the ER, we pre-
treated the Jurkat cells with 1 mM MDEB for 10 min. To induce the Ca2+ release from the 
ER, Jurkat cells were then treated with 10 µg/ml PHA, allowing synthesis of IP3, activation 
of the IP3R and Ca
2+ release from the ER [37].
In Ca2+-free HBS, PHA induced a rapid and transient increase of [Ca2+]cyt: the 
[Ca2+]cyt peaked at 39 ± 7 nM after  2 min (Fig. 7A). When 1 mM MDEB was added 5 min 
prior to PHA, the [Ca2+]cyt increase was not significantly different as both curves
superimposed: [Ca2+]cyt peaked at 29 ± 4 nM after  2 min. The same kind of curves was 
obtained with 10 mM MDEB (data not shown). These experiments therefore strongly suggest 
that MDEB had no effect on the PHA-induced Ca2+ release from the ER.
As the response to PHA was the same in the absence or the presence of 1 mM MDEB, 
it seems that the ER Ca2+ amount was not modified by MDEB. To confirm these results, we 
performed the same kind of experiment in a HBS medium where all the Na+ ions were 
replaced by Li+, and where 0.4 µM HgCl2 was added: this protocol allows the blockade of the 
NCX and the PMCA respectively. Therefore, when TG is added, all the Ca2+ ions are 
released by the ER but could neither be pumped back to the ER, nor exit from the cell by 
NCX or PMCA, and are thus trapped in the cytosol [48].
As shown in Figure 7B, in absence of MDEB, TG induced a rapid increase of 
[Ca2+]cyt, that peaked after  90 s, reaching a plateau of  100 nM. When the cells were pre-
treated with 1 mM MDEB for 10 min, TG induced the same kind of [Ca2+]cyt increase and 
plateau level, indicating again that the ER Ca2+ amount was not modified by presence of 
MDEB.
In order to take into account the possibility that in the above-mentioned experiments 
MDEB did not reach the IP3Rs and SERCA pumps because it would be cell impermeant, we 
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also performed experiments on permeabilized cells. We have previously demonstrated that 
gentle permeabilization of the plasma membrane of cells grown in monolayers, followed by 
45Ca2+ loading of the ER stores and measurement of the unidirectional Ca2+ efflux allows for 
a quantitative analysis of IP3R activity in the presence of various activators or inhibitors [25, 
38, 49-51]. As this type of experiment can however not be performed on cells in suspension 
or loosely attached cell lines, we used as model system the L15 fibroblast cell line 
overexpressing IP3R1 [51]. MDEB between 10 µM and 1 mM was present during the 
complete release phase and IP3-induced Ca
2+ release was induced by addition of 0.7 µM IP3
for 2 min (Fig. 7C). As can be observed (Fig. 7C and D) MDEB up to 1 mM had no effect on 
IP3-induced Ca
2+ release.
In the same model system we investigated whether MDEB could affect the ER 
loading capacity by adding the compound during the loading phase. However, even high 
MDEB concentrations only very slightly affected active Ca2+ uptake in the ER (at 100 M 
MDEB 98  2 % and at 1 mM MDEB 94  2 % active Ca2+ uptake remaining, n=3) 
indicating only a very weak inhibitory effect on SERCA pump activity.
3.7. MDEB differently modifies the [Ca2+]cyt rise induced by suboptimal (1 µg/ml) and 
optimal (10 µg/ml) concentrations of PHA
Having shown that MDEB was able to increase the Ca2+ influx amplitude, we next 
performed experiments to see whether MDEB had a functional effect on the IL-2 synthesis
induced by PHA. IL-2 is synthesized by activated cells, and is absolutely necessary for T cell 
proliferation and immune function [52]. IL-2 synthesis requires an influx of extracellular 
Ca2+ ions through SOCE channels during at least 2 hours, while a short-term Ca2+ rise is not 
sufficient [5-7, 53].
Prior to performing the IL-2 synthesis experiment, we tested the effect of MDEB on 
the [Ca2+]cyt of PHA-stimulated Jurkat cells during the 1
st 10 min as well as, after 3 and 24h 
of stimulation (Fig. 8). Jurkat cells had a resting [Ca2+]cyt of 121  14 nM (n > 50). After 
stimulation with 10 µg/ml PHA, a concentration known to fully activate Jurkat cells
[54],[Ca2+]cyt quickly rised to 424  34 nM (n = 5, p < 0.01) for a time period that exceeded
the complete duration (10 min) of the experiment (Fig.8A). After 3h of 10 µg/ml PHA 
stimulation, the [Ca2+]cyt of Jurkat cells had started to decrease (198  47 nM, n = 4, p < 0.01) 
and was back to the level observed in control cells after 24 h (126  21 nM, n = 5, Fig. 8C).
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In contrast, 1 mM MDEB induced a very slight and transient increase of the resting 
[Ca2+]cyt to 141  2 nM (Fig. 8A). After 10 min, the resting [Ca2+]cyt of MDEB-treated cells 
was not different from the value measured in untreated cells (104  13 nM vs. 121  14 nM, n 
> 50). Longer exposures to 1 mM MDEB (3 and 24h) did not modify the resting [Ca2+]cyt that 
were 127  9 nM (n = 3) and 118  13 nM (n = 4) respectively (Fig. 8C). 30 µM 2-APB, 
known to block the SOCE, significantly decreased the resting [Ca2+]cyt to 60  5 nM (n = 3, p 
< 0.01), showing that under resting conditions, some channels responsible for the SOCE are 
already open, and that they are sensitive to inhibition by 2-APB as well as to potentiation by 
MDEB (Fig. 8A).
Finally, when the Jurkat cells were stimulated with 10 µg/ml PHA in the presence of 1 
mM MDEB, the [Ca2+]cyt increase was significantly enhanced to 780  53 nM after 10 min (n 
= 5, p < 0.01, Fig. 8A). After 3 h of 10 µg/ml PHA stimulation in the presence of MDEB, and 
although the [Ca2+]cyt of the cells had started to decrease, it still remained significantly higher 
(251  36 nM, n = 3, p < 0.01) than after PHA stimulation in the absence of MDEB. 
Moreover, after 24h of the same treatment, the resting [Ca2+]cyt was also still higher (190  8 
nM, n = 3, p < 0.01) than in untreated cells (Fig. 8C). These results show that MDEB 
reinforced the [Ca2+]cyt increase in both amplitude and time.
When the Jurkat cells were stimulated with a suboptimal concentration of PHA (1 
µg/ml, [54]), [Ca2+]cyt rised slowly to  190  2 nM ( n = 4, p < 0.01, Fig. 8B) after 10 min 
value. Even if after 3h, [Ca2+]cyt started to decrease, it was still higher than in control cells: 
166  4 nM (n = 3) vs.121  14 nM (p < 0.01) and was back to the control [Ca2+]cyt after 24h 
(112  6 nM, n = 4, Fig. 8 D).
The stimulation of the cells with 1 µg/ml PHA in presence of 1 mM MDEB, induced 
a faster rise of [Ca2+]cyt that peaked at 224   6 nM (n = 4, p < 0.01), followed by a slow 
decrease to 197  6 nM after 10 min (n = 4, p < 0.01, Fig. 8B). Interestingly, after 10 min, the 
[Ca2+]cyt rises of cells stimulated with 1 µg/ml PHA in absence and presence of 1 mM MDEB 
were not significantly different (190  2 nM vs. 197  6 nM). Furthermore, the use of 1 µg/ml 
PHA + 1 mM MDEB could not induce a rise similar to the one obtained with 10 µg/ml PHA 
after 10 min (197  6 nM vs. 424  34 nM, p < 0.01). Surprisingly, after 3h, [Ca2+]cyt was 
significantly lower than in controls cell (96  4 nM, (n = 4) vs. 121  14 nM, p < 0.05, Fig. 
8D) or in cells only stimulated with 1 µg/ml PHA (166  4 nM, p < 0.01), and came back to 
control values after 24 h (114  5 nM, n = 4). Thus, the presence of MDEB led after 
treatment with 1 µg/ml PHA to a more transient [Ca2+]cyt rise that totally finished after 3h.
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3.8. MDEB inhibits IL-2 synthesis induced by PHA
We next measured the synthesis of IL-2 by the Jurkat cells stimulated for 24 h with 1 
or 10 µg/ml PHA in the presence or absence of MDEB. To compensate for any effect of 
MDEB on cell survival, we first controlled their viability by counting the living vs. dead cells 
in the presence of Trypan blue. In the absence of any stimulation, the percentage of dead cells 
in the Jurkat cell culture represented 4.4   1.8% (n > 20).
Even if MDEB did not change the proportion of dead cells when stimulated by 1 
µg/ml PHA (from 2 to 7.2% of dead cells, Fig. 9A), increasing MDEB concentrations
induced in the presence of 10 µg/ml PHA, a progressive rise of the cell death to reach a value 
of 28.2  2.8 % at 1 mM MDEB (n = 3, p < 0.01, Fig. 9A). This means that while almost all 
the Jurkat cells stimulated by 1 µg/ml PHA were able to synthetize IL-2, only about  ¾ of 
them would be able to do so when stimulated by 10 µg/ml PHA stimulation.
In the absence of PHA stimulation, MDEB was not able to induce the synthesis of IL-
2 at any concentration (Fig. 9B), indicating that the small increase in resting [Ca2+]cyt
observed with 1 mM MDEB (Fig. 7A) was not enough to activate the Jurkat cells. However, 
MDEB significantly decreased in a concentration-dependent way the IL-2 synthesis
(expressed as IL-2 synthesized per 100% living cells) elicited by 24 h of treatment with 1 
(grey bars) or 10 µg/ml (black bars) PHA by respectively ~ 70% (24  1 vs. 86  2 pg/ml, p < 
0.01) and ~ 30% (113  5 vs. 168  3 pg/ml, p < 0.01) at the maximal MDEB concentration 
used (1 mM). Surprisingly, no MDEB potentiation of the IL-2 synthesis was observed at the 
sub-optimal concentration of 1 µg/ml PHA.
These results indicate that MDEB is an inhibitor of IL-2 synthesis and of Jurkat T cell 
activation.
3.9. MDEB induces apoptosis of Jurkat cells stimulated by 10 µg/ml PHA
Staining with Trypan blue showed that MDEB increased the number of dead cells 
when stimulated with 10 µg/ml PHA. We next performed a TUNEL assay to assess the 
capacity of MDEB to induce apoptosis of the Jurkat cells. In control conditions, less than 1%
of cells were apoptotic (Fig. 10 A and B). After stimulation with 10 µg/ml PHA, or in the 
presence of 1 mM MDEB, no increase in apoptosis level was detectable (Fig. 10A). 
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Remarkably, only PHA-stimulated cells treated with 1 mM MDEB demonstrated a significant 
time-dependent level of apoptotic cells (27 ± 3%, n = 3, Fig. 10B).  
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4. DISCUSSION
During the past decade, several effectors of the SOCE have been developed, and 
among them, 2-APB is probably the one with the most interesting properties: at low 
concentrations, it potentiates the SOCE, while at higher concentrations it is inhibitory. 
However, despite these properties, 2-APB is not specifically targeting the SOCE, and is a 
well-established modulator of other Ca2+ transporters: SERCA, IP3R and some TRP channels
[21, 23, 25, 55, 56].
In a recently published work [47], we showed that the use of 2-APB analogues can 
help to understand which part of the molecule is requested for the potentiation or the 
inhibition capacity. Thus, the two phenyl groups seem to play a key role in the sensitivity to 
the inhibition process, the ethanolamine group plays a role only in the inhibition, and the 
central BOC in the potentiation. 
Even if the Orai1 proteins seem to form the pore of the channel allowing the SOCE in 
the Jurkat cells, it has been shown that several other proteins could associate with Orai1: 
TRPC1 [57], CRACR2A [58], SARAF [59] and junctate [60]. Thus, the SOCE channel 
molecular nature is not restricted only to Orai1 proteins, and SOCE studies should be 
performed with "complete" SOCE channels. Furthermore, the expression ratio of 
Orai1/STIM1 is known to modify the effect of 2-APB on the SOCE. For all these reasons, we 
have chosen to study the effect of MDEB in more physiological conditions, by using cell 
lines.
In this work, we focussed our attention to MDEB, which is a derivative of the 2-APB 
molecule restricted to its BOC. When used on leukocyte cell lines and two breast cancer cell 
lines, MDEB has unique properties: this molecule can only potentiate the SOCE, and is 
totally devoid of inhibition capacity. Furthermore, unlike 2-APB, MDEB is not able to 
influence the Ca2+ release by the IP3R of the ER. Noteworthy, MDEB cannot modify the Ca
2+
amount of the ER, probably due to a lack of effect on the SERCA. Thus, this molecule seems 
to have a better selectivity for the SOCE than the other 2-APB analogues [30, 31].
Furthermore the cell lines we used showed different sensitivity to MDEB: with a potentiation 
constant of  ~ 20 µM, breast cancer MDA-MB231 and BT-20 cells SOCE are more sensitive 
to MDEB than leukocyte cell lines SOCE (between 44 and 66 µM). This difference could
reflect differences in the SOCE channel composition and/or the expression ratio between 
Orai1 and the activating protein STIM1. Indeed, it is known that the sensitivity to 2-APB 
depends on the relative expression ratio between Orai1 and STIM1 proteins [61], and the 
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same could be possible for the sensitivity to MDEB. Sub-unit composition of the SOCE is 
still under debate, and each type of cells could have its own type of SOCE according to the 
expressed proteins. Thus, Orai1 proteins could associate to different TRPC proteins to form a 
SOCE, like TRPC1, TRPC3 or TRPC6 [57, 62]. Noteworthy, studies on Orai1-deficient 
lymphocytes and fibroblasts clearly established a central role for Orai1 in Ca2+ entry in these 
cells [44]. In our hands, we confirmed that lymphocytes lacking Orai1 expression were 
devoid of a discernible SOCE, and in addition demonstrated that MDEB was useless to evoke 
SOCE. Previous studies have also shown that Orai1 is important for the SOCE of MDA-
MB231 cells and that when expression of Orai1 is reduced in those cells by using siRNA 
protocols, the SOCE is hugely decreased [17, 63]. In line with this, MDEB was in our hands 
also devoid of any significant SOCE potentiation ability in MDA-MB231 cells with a 
reduced Orai1 protein expression. Thus, it seems that the potentiating effect of MDEB on 
SOCE is linked to the presence of Orai1 proteins.
Interesting is the comparison between MDEB and 2-ABB: 2-ABB resembles MDEB 
with the main difference that an ethanolamine group replaces the methyl group (the two ethyl 
groups are also replaced by two butyl groups, but this change probably does not play a main 
role in the difference of the behaviour of the two molecules). 2-ABB has, like 2-APB, a dual 
effect on SOCE [33]. Thus, we can conclude that the B-N internal coordinate of 2-ABB (and 
2-APB) has an inhibitory ability. However, dimesityl borinic acid (DMBA), a 2-APB
analogue without the ethanolamine group, and not able to form the B-N internal coordinate, is 
a strong inhibitor of the SOCE [33]. Thus, the structure function analysis of 2-APB leads to a
complex conclusion: the BOC is an absolute requirement for the molecule to be potentiating, 
and the phenyl groups and/or the B-N internal coordinate are needed for the inhibitory 
capacity of the molecule. Noteworthy, we can hypothesize that 2-APB inhibits the SOCE by 
two ways: via the phenyl rings (as with DMBA) or by the B-N internal coordinate (as with 2-
ABB). 
The great advantage of MDEB is that this molecule is devoid of any rings or internal 
coordinate. Thus, it confirms that the BOC is responsible for the potentiating capacity of the 
borinate esters and we can hypothesize that any molecule with a BOC and without any rings 
or internal coordinate will have the ability to only potentiate the SOCE. It also confirms that 
the presence of rings or B-N internal coordinate plays a key role in the sensitivity of the 
SOCE to the modulation by the borinate esters: thus, if we count the number of closed
structures, we have the following sequence of efficacy: DPBA (4 phenyl groups = 4 rings) > 
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2-APB (2 phenyl groups + 1 internal coordinate ~ 3 rings) > 2-ABB (1 internal coordinate ~ 
1 ring) > MDEB (0 ring) [33].
Another main difference between MDEB and the ring-containing borinate esters is 
that this molecule is not able to inhibit the Ca2+ release by the ER. One of the limits of 2-APB 
and its analogues is this lack of specificity between Ca2+ release and Ca2+ influx. Mikoshiba’s 
group had designed analogues with more selectivity for the Ca2+ influx [30, 31]. However, 
these molecules could still inhibit Ca2+ release by the ER. Furthermore, investigating both 
intact and permeabilized cells we could demonstrate that MDEB only minimally affects the 
SERCA activity. Although the present work therefore clearly shows that two of the main 
targets of 2-APB, are nearly completely insensitive to this analogue, more work is still 
needed to further document the specificity of MDEB, and especially to investigate whether 
the compound can affect TRP channels. 
In this work, we also demonstrated that the special properties of MDEB could be used 
to selectively inhibit or eliminate target cells. MDEB is able to induce a very faint increase of 
[Ca2+]cyt by itself. In contrast, addition of 30 µM 2-APB decreases the [Ca
2+]cyt, showing that 
some Orai1 channels are already open to regulate [Ca2+]cyt allowing the constant replenishing 
of the ER with Ca2+ ions under the control of STI 2 [64]. However this tiny and transient 
MDEB induced [Ca2+]cyt increase is not sufficient to activate the Jurkat T cells and the
synthesis of IL-2. We expected MDEB to potentiate the IL-2 synthesis of cells stimulated by 
a suboptimal concentration of PHA. On the contrary after 24 h of treatment with 1 µg/ml 
PHA, 1 mM MDEB was already able to inhibit the IL-2 synthesis. Surprisingly, even if 
MDEB 1 mM potentiates the [Ca2+]cyt rise induced by 1 µg/ml PHA, [Ca
2+]cyt rapidly returns 
to the level of control cells. We can hypothesize that in the first minutes of stimulation, the 
Jurkat cells increased their capacity to remove Ca2+ ions from the cytosol as usual, except that 
the stimulation is not optimal, not allowing the full mobilisation of Ca2+ ions from the ER. In 
the absence of MDEB, the increase of [Ca2+]cyt is weaker, the cells did not fully activate the 
extrusion of Ca2+ ions: this rise can last for at least 3h, allowing the full synthesis of IL-2.
At higher concentration of PHA (10 µg/ml), MDEB induced the cell death of ~ 30%
of the Jurkat cells. Furthermore, the IL-2 synthesis of the remaining cells is also reduced by ~ 
30%. Thus, MDEB, by potentiating the Ca2+ influx, inhibits the synthesis of IL-2 induced by 
full activation. Interestingly, SKF96365 inhibition of IL-2 synthesis in peripheral blood 
lymphocytes did not affect their viability [53]. MDEB is by itself not toxic for the cells, but is 
toxic for 10 µg/ml PHA-stimulated cells. Thus after 6h of 10 µg/ml PHA + 1 mM MDEB, a 
significant part of the cells have shown apoptotic signs, like DNA fragmentation that reached 
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almost one third after 24h. Since the discovery of the Orai1 protein as pore of the SOCE
channels, several mutations have been created which revealed some crucial parts of the 
protein. The glycine in position 98 forms a hinge in the first transmembrane domain. Even if 
the G98A mutation abolished the SOCE and has a dominant-negative action on the wild type
Orai1 subunit, G98P and G98D mutations create constitutively active Orai1 channels [65]. 
This constitutive SOCE induces an increase of the resting [Ca2+]cyt compared to the wild type
SOCE, leading to cell death 2 days after transfection [65]. As shown in the present study, 
MDEB extends the [Ca2+]cyt rise induced by PHA. The inability of the cells to regain in the 
presence of MDEB a normal [Ca2+]cyt after PHA stimulation seems to induce their cell death 
by apoptosis.
In contrast to SOCE inhibitors like SKF96365, MDEB decreases the Jurkat cell 
activation by two ways according to the intensity of the cell stimulation:
(i) by shortening the [Ca2+]cyt rise at suboptimal PHA concentration, MDEB impairs 
the full activation of the machinery leading to IL-2 synthesis,
(ii) by inducing the cell apoptosis of an increasing number of cells at optimal PHA 
concentration. This latter property could be of interest as MDEB targets only activated cells, 
and does not seem to be toxic for untreated cells. Thus, we can hypothesize that cells where 
the [Ca2+]cyt is already increased could be sensitive to MDEB. In a previous work we showed 
that the [Ca2+]cyt of B cells expressing the Epstein-Barr Virus oncogenic protein LMP-1 rises 
to almost 200 nM due to an increase of the SOCE amplitude [48, 66]. The next step of our 
work will be to test the ability of MDEB to induce the apoptosis of these LMP-1 – expressing 
B cells. For memory, LMP-1 is expressed by infected cells of some Hodgkin diseases, 
polyclonal lymphomas or the nasopharyngeal carcinoma for example [67].
In summary, we have characterized the first molecule having only a potentiating 
ability on SOCE from different cell lines. It has kept the potentiating ability of the 2-APB 
molecule, but lost the inhibitory capacity. Thus, it could represent the first member of a 
promising new compound family, able for example to regulated the activity of immune cells
or for inducing the apoptosis of target cells.
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7. FIGURE LEGENDS
Figure 1: Structure of 2-APB and analogues.
Structures of 2-aminoethoxydiphenyl borate (2-APB, 1), 2-aminoethoxydibutyl borate (2-
ABB, 2), methyl-diethylborinate (MDEB, 3) and trimethylborate (TMB, 4).
Figure 2: MDEB potentiates the divalent ion influx in Jurkat cells.
A. Cytosolic Ca2+ concentration ([Ca2+]cyt) measurement in Jurkat cells using Fura-2 
fluorescence. Cells were treated for 10 min with thapsigargin (1 µM, arrow i) to allow Ca2+
release from ER and opening of the SOCE channels. After 10 min, 1 mM CaCl2 was added, 
allowing Ca2+ entry through the SOCE channels. MDEB at the indicated concentrations was
applied 30 s prior to CaCl2 (arrow ii). The SOCE inhibitor GdCl3 (1 µM) was added at the 
same time as MDEB. Results are representative of 5 experiments.
B. 2-APB, 2-ABB and MDEB regulate in a different way SOCE in Jurkat cells, while TMB 
is ineffective. Experiments were performed as in Figure 2A, and the peak [Ca2+]cyt was 
expressed as % of the peak [Ca2+]cyt recorded in the absence of any compounds. Compounds 
were added 30 s prior to CaCl2. Results are expressed as mean ± SEM (n ≥ 3).
C. Mn2+ quenching of Fura-2 in Jurkat cells is enhanced by 1 mM MDEB. Cells were pre-
treated for 10 min with thapsigargin (TG, 1 µM) to allow Ca2+ release from the ER and 
opening of the SOCE channels. 60 s after beginning of the recordings, 100 µM MnCl2 was 
added. At 120 s, 1 mM MDEB was added. Fluorescence of Fura-2 was recorded at 510 nm 
after excitation at 360 nm. Results are representative for 3 experiments and express the
fluorescence relative to that prior to MnCl2 addition. The dotted line represents the slope of 
Fura-2 quenching by Mn2+ ions in absence of MDEB. Results are representative of 4
experiments.
Figure 3: MDEB potentiates SOCE in other leukocyte cell lines.
The same protocol as in Figure 2 was used on Burkitt B lymphoma (BL-41) and monocytic
(U937) cells.
A. MDEB dose-response curves could be fitted with a simple sigmoidal curve, giving 
potentiation constant of 44 ± 11 µM (Jurkat cells, n = 5), 58 ± 7 nM (BL-41 cells, n = 4) and 
66 ± 12 nM (U937 cells, n = 5).
B. MDEB has no effect on the SOCE of Orai1-deficient B cells. The same protocol as in 
Figure 2A was used on a lymphoblastoid cell line expressing wild type Orai1 (B-Orai1 wt)
and an Orai1-deficient lymphoblastoid cell line (B-Orai1 deficient) established from a patient 
presenting a SCID phenotype due to a double mutation in the Orai1 gene allele, resulting in 
the absence of Orai1 protein in the plasma membrane of B cells [44]. At t = 800s, 1mM 
MDEB was added.
C. MDEB only potentiates SOCE when Orai1 is expressed. Mn2+ experiments were 
performed as in Figure 2C. A comparison was performed between a lymphoblastoid cell line
expressing wild type Orai1 (B-Orai1 wt) and an Orai1-deficient lymphoblastoid cell line (B-
Orai1 deficient). Results are representative of 5 experiments. Recordings done on Orai1 
deficient cells are noiser due to a weaker Fura-2 loading.
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Figure 4: MDEB potentiates SOCE in two breast cancer cell lines.
The same protocol as in Figure 2 was used on MDA-MB231 and BT20 cells.
A. MDEB dose-response curves could be fitted with a simple sigmoidal curve, giving 
potentiation constant of 44 ± 11 µM (Jurkat cells, n =5), : 25 ± 7 nM (MDA-MB231, n = 4)  
and 14 ± 2 µM (BT20, n =4).
B. MDA-MB231 were transfected with 100 nM siRNA against Orai1 or a control siRNA. 
Proteins were extracted after 72h. Western-blotting was then conducted to assess the Orai1 
protein knockdown. Actin was used as a control and showed no difference in the quantity of 
protein loaded per lane (not shown). The use of 100 nM siRNA against Orai1 mRNA 
decreased expression of Orai1 protein by 78 ± 6 % (n=3).
C. Decreasing Orai1 expression impaired the SOCE of MDA-MB231. The same protocol 
used in figure 2A was used on control siRNA-transfected MDA-MB231 (“control siRNA”) 
cells and Orai1 siRNA-transfected MDA-MB231 (“Orai1 siRNA”). At t = 800s, 1mM 
MDEB was added and was only efficient on cells still expressing normal Orai1 protein level.
Results are representative of 5 experiments.
Figure 5: MDEB partly counteracts the inhibition of the SOCE by 2-ABB, but not that 
by 2-APB.
[Ca2+]i measurement was performed using Fura-2 in Jurkat cells in the presence of either 
MDEB and 2-APB (A and B) or MDEB and 2-ABB (C and D). MDEB, 2-APB and 2-ABB 
were used at a concentration of 100 µM. A and B. Cells were treated for 600 s with 
thapsigargin (1 µM, arrow i) in Ca2+-free medium to allow Ca2+ release from the ER and 
opening of the SOCE channels. Then, 1 mM CaCl2 was added, allowing Ca
2+ entry through 
the SOCE channels. 2-APB, MDEB or 2-APB + MDEB were applied 30 s prior to CaCl2 (A 
and B, arrow ii). In competition experiments, MDEB was applied 30 s after CaCl2 addition to
cells treated with 2-APB (“2-APB prior MDEB”, A, arrow iii) or 2-APB was applied 30 s 
after CaCl2 addition to cells treated with MDEB (“MDEB prior 2-APB”, B, arrow iii). C and 
D: similar experiments were performed as in A and B, except that 2-APB was replaced in all 
cases by 2-ABB. Results are representative for 5 experiments. E. MDEB dose-response 
curves were obtained as in figure 2B. The various concentrations of MDEB were added 30s 
prior CaCl2 with different concentrations of 2-APB. The curves could be fitted with a mono-
exponential curve.
Figure 6: MDEB directly enhances ICRAC.
Jurkat cells were dialyzed with a pipette solution containing 10 mM BAPTA to induce store 
depletion, and the whole-cell current was measured in the presence of extracellular Ca2+.
A. ICRAC was evoked by a 100 ms pulse at -100 mV from a holding potential of 0 mV. Bath 
medium contained 0, 1 or 10 mM CaCl2. Results are representative for 3 experiments.
B. Time courses of ICRAC recorded with a pipette solution containing 10 mM BAPTA or 10 
mM EGTA, in the presence of 10 mM external CaCl2. Patch disruption allowed appearance 
of an inward current that peaked quickly with EGTA or after ~1 min with BAPTA in the 
pipette. Then, the current decayed. At t = 6 min, the 1 mM MDEB was directly added to the 
bath and ICRAC amplitude immediately increased. At t = 6 min, 1 µM GdCl3 was added. The 
remaining Gd3+ ions - resistant current was considered as the leak current and subtracted from 
the current amplitude recordings. These recordings are typical of 3 experiments.
C. Same protocol as in Fig. 6A. ICRAC was recorded in the presence of 10 mM extracellular 
CaCl2 before MDEB addition (black line), at the peak of 1 mM MDEB potentiation (red 
line), and after 1 µM GdCl3 addition (blue line).
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D. Current-voltage relationships of the currents recorded in the presence of 10 mM CaCl2
before (black trace) and after (red trace) 1 mM MDEB addition. Results are representative for
5 experiments
Figure 7: MDEB does not inhibit the Ca2+ release from the ER.
A. Jurkat [Ca2+]cyt was measured as in Figure 2. To induce Ca
2+ release by the ER, cells were 
treated at t = 30 s with 10 µg/ml PHA, which is known to induce the synthesis of IP3 and 
subsequent Ca2+ release through the ER IP3Rs. When indicated, 1 mM MDEB was added 5 
min prior to PHA stimulation. Results are express as mean ± SEM (n = 3).
B. To estimate the Ca2+ amount of the ER, Jurkat cells were placed in Li+-HBS, in order to 
impair the activity of the Na+/Ca2+ exchanger and in the presence of 0.4 µM HgCl2 to block 
the activity of the plasma membrane Ca2+ ATPases. When indicated, 1 mM MDEB was 
added 5 min prior thapsigargin (TG) addition used to induce the Ca2+ release by the ER.
Results are express as mean ± SEM (n = 3). 
C. and D. The effect of MDEB on the IP3–induced Ca
2+ release was investigated in 
permeabilized L15 fibroblasts. C. The ER Ca2+ stores of saponin-permeabilized cells were 
loaded until steady-state with 45Ca2+ and release was induced by incubation in a Ca2+-free 
efflux medium in the presence of thapsigargin (10 M) and the indicated concentration of 
MDEB. Samples were taken every 2 minutes. IP3 (0.7 M) was added for 2 min (white bar) 
and IP3-induced Ca
2+ release measured. 45Ca2+ release is expressed as fractional loss, i.e. the 
amount of Ca2+ released during 2 min relative to the total amount of Ca2+ present at that 
moment in the stores. Representative traces are shown for 6 independent experiments, each 
performed in two-fold. Standard deviation is indicated when larger than the symbol. D. Bar 
graph showing the IP3-induced Ca
2+ release in the presence of the indicated MDEB 
concentrations. The fractional loss induced by IP3 in the absence of MDEB was taken as 
100% and all values are shown relative to this value. Average  S.E.M is shown for 6 
independent experiments, each performed in two-fold.
Figure 8: MDEB modifies the [Ca2+]cyt rise of PHA-stimulated Jurkat cells.
Jurkat cell [Ca2+]cyt was measured using Fura-2 fluorescence in the presence of 1 mM 
extracellular CaCl2. Cells were stimulated with 1 mM MDEB, 30 µM 2-APB, 1 (B and D) or 
10 µg/ml PHA (A and C) alone or with MDEB. Statistically significant differences from 
control are indicated by: *: p < 0.01, #: p< 0.05.
A. At t = 30 s, cells were kept untreated (“control”, black line), treated by 1 mM MDEB
(green line), or stimulated with 10 µg/ml PHA alone (blue line) or in the presence of 1 mM 
MDEB (red line). 30 mM 2-APB was used as a control (grey line). Results are representative 
for 3 experiments.
B. At t = 30 s, cells were kept untreated (“control”, black line), treated by 1 µg/ml PHA alone 
(red line), or with 1 mM MDEB (green line). A recordings made with 10 µg/ml PHA was 
added for comparison. Results are representative for 3 experiments.
C. Several batches of Jurkat cells were stimulated in cell culture conditions for 3 and 24 h 
with 10 µg/ml PHA alone or in the presence of 1 mM MDEB, or treated with 1 mM MDEB 
alone. After Fura-2 loading, the cells were placed in a 1 mM CaCl2-containing HBS medium, 
and their mean [Ca2+]cyt was calculated based on the Fura-2 fluorescence. Values at 10 min 
were measured at the end of the experiments shown in Figure 8A. Results are mean ± SEM 
from 3 experiments. The red line represents the mean resting [Ca2+]cyt of untreated cells ( n = 
10).
D. Same protocol as in Figure 8C except that cells were stimulated with 1 µg/ml PHA alone 
or in the presence of 1 mM MDEB, or treated with 1 mM MDEB alone. The red line 
represents the mean resting [Ca2+]cyt of untreated cells ( n = 10).
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Figure 9: MDEB inhibits IL-2 synthesis of PHA-stimulated Jurkat cells by decreasing 
cell viability and/or IL-2 synthesis capacity.
Jurkat cells were stimulated by 1 or 10 µg/ml PHA in the presence of MDEB at the indicated 
concentrations. After 24h dead cells were counted using a Malassez hematimeter (A) or the 
supernatants were collected, and IL-2 concentrations were measured by Elisa. The values of 
produced IL-2 were corrected by the number of living cells (B). Statistically significant 
differences from control are indicated by: *: p < 0.01, #: p< 0.05.
Figure 10: MDEB induces apoptosis of 10 µg/ml PHA-stimulated Jurkat cells.
Cells were stained with DAPI (blue, top) to visualize the nuclei and with the TUNEL method 
(green, bottom) to visualize apoptotic cells. Each staining was merged with the phase contrast 
image to visualize whole cells. In control conditions or after stimulation by 10 µg/ml PHA or 
1 mM MDEB for 6, 12 or 24 h, no apoptotic cells were detectable. Only 10 µg/ml PHA-
stimulated cells treated with 1 mM MDEB demonstrated a significant level of apoptotic cells.
A. Representative pictures of cells after 24h of treatment with 10 µg/ml PHA alone or with 1 
mM MDEB, or 1 mM MDEB alone.  Scale bar = 10µm.
B. The number of apoptotic cells was counted at 6, 12 and 24 h of treatment. Only 10 µg/ml 
PHA + 1 mM MDEB induced a significant increase of apoptosis. Statistically significant 
differences from control are indicated by: *: p < 0.01.
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